Sandoz is suing Amgen over alleged patent abuse delaying the US launch of a biosimilar to the autoimmune drug Enbrel.

The news came on Friday of the approval of Amjevita, Amgen’s copy of adalimumab, and only the fourth biosimilar to be approved in the US. The FDA has approved it across six different indications ...

Two adalimumab biosimilars (Amjevita and Imraldi) worked as well for moderate to severe psoriasis as the original brand-name product (Humira) for patients either starting or switching treatment ...

Amgen already has its Humira biosimilar Amjevita approved by the FDA, but will not begin selling it until 2023 after reaching an agreement with AbbVie last year. The deal was seen as an admission ...

As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this consolidation of the drug supply chain could undercut competition.